Aberrant Expression of OX1 Receptors for Orexins in Colon Cancers and Liver Metastases: An Openable Gate to Apoptosis

Cancer Research

Volumn 71, Issue 9, 2011, Pages 3341-3351

  Voisin, Thierry ^a   El Firar, Aadil ^a   Fasseu, Magali ^a   Rouyer Fessard, Christiane ^a   Descatoire, Véronique ^a   Walker, Francine ^a   Paradis, Valérie ^a   Bedossa, Pierre ^a   Henin, Dominique ^a   Lehy, Th́erèse ^a   Laburthe, Marc ^a,b  

^a INSERM   (France)

^b CENTRE DE RECHERCHE BIOMÉDICALE BICHAT BEAUJON CRB3   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; FLUOROURACIL; MESSENGER RNA; OREXIN 1 RECEPTOR; OREXIN A;

ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; COLON CANCER; COLONOCYTE; CONTROLLED STUDY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; INTESTINE CELL; LIVER CELL; LIVER METASTASIS; MOUSE; NONHUMAN; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR XENOGRAFT;

ADENOCARCINOMA; ANIMALS; APOPTOSIS; CACO-2 CELLS; CELL LINE, TUMOR; COLONIC NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FLUOROURACIL; HCT116 CELLS; HT29 CELLS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LIVER NEOPLASMS; NEUROPEPTIDES; RATS; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, NEUROPEPTIDE;

EID: 79955518027     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-3473     Document Type: Article

References (44)

1. Taketo MM, Edelmann W. Mouse models of colon cancer. Gastroenterology 2009;136:780-98.
2. Markowitz SD, Bertagnolli MM. Molecular origins of cancer: molecular basis of colorectal cancer. N Engl J Med 2009;361:2449-60.
3. Rozengurt E. Neuropeptides as growth factors for normal and cancerous cells. Trends Endocrinol Metab 2002;13:128-34. (Pubitemid 36734003)
4. Wolpin BM, Mayer RJ. Systemic treatment of colorectal cancer. Gastroenterology 2008;134:1296-310.
5. Bhola NE, Grandis JR. Crosstalk between G-protein-coupled receptors and epidermal growth factor receptor in cancer. Front Biosci 2008;13:1857-65. (Pubitemid 351599738)
6. Rouet-Benzineb P, Rouyer-Fessard C, Jarry A, Avondo V, Pouzet C, Yanagisawa M, et al. Orexins acting at native OX(1) receptor in colon cancer and neuroblastoma cells or at recombinant OX(1) receptor suppress cell growth by inducing apoptosis. J Biol Chem 2004;279: 45875-86.
7. Sakurai T, Amemiya A, Ishii M, Matsuzaki I, Chemelli RM, Tanaka H, et al. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell 1998;92:573-85. (Pubitemid 28101119)
8. De Lecea L, Kilduff TS, Peyron C, Gao X, Foye PE, Danielson PE, et al. The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc Natl Acad Sci U S A 1998;95:322-7. (Pubitemid 28103952)
9. Ohno K, Sakurai T. Orexin neuronal circuitry: role in the regulation of sleep and wakefulness. Front Neuroendocrinol 2008;29:70-87.
10. Voisin T, Rouet-Benzineb P, Reuter N, Laburthe M. Orexins and their receptors: structural aspects and role in peripheral tissues. Cell Mol Life Sci 2003;60:72-87. (Pubitemid 36223118)
11. Heinonen MV, Purhonen AK, Makela KA, Herzig KH. Functions of orexins in peripheral tissues. Acta Physiol 2008;192:471-85. (Pubitemid 351322731)
12. Johren O, Neidert SJ, Kummer M, Dendorfer A, Dominiak P. Preproorexin and orexin receptor mRNAs are differentially expressed in peripheral tissues of male and female rats. Endocrinology 2001; 142:3324-31. (Pubitemid 32681736)
13. Laburthe M, Voisin T, El Firar A. Orexins/hypocretins and orexin receptors in apoptosis: a mini-review. Acta Physiol 2010;198:393-402.
14. Johansson L, Ekholm ME, Kukkonen JP. Multiple phospholipase activation by OX(1) orexin/hypocretin receptors. Cell Mol Life Sci 2008;65:1948-56.
15. Voisin T, El Firar A, Rouyer-Fessard C, Gratio V, Laburthe M. A hallmark of immunoreceptor, the tyrosine-based inhibitory motif ITIM, is present in the G protein-coupled receptor OX1R for orexins and drives apoptosis: a novel mechanism. FASEB J 2008;22:1993-2002. (Pubitemid 351811475)
16. El Firar A, Voisin T, Rouyer-Fessard C, Ostuni MA, Couvineau A, Laburthe M. Discovery of a functional immunoreceptor tyrosinebased switch motif in a 7-transmembrane-spanning receptor: role in the orexin receptor OX1R-driven apoptosis. FASEB J 2009; 23:4069-80.
17. Watson AJ. An overview of apoptosis and the prevention of colorectal cancer. Crit Rev Oncol Hematol 2006;57:107-21. (Pubitemid 43139699)
18. Huerta S, Goulet EJ, Livingston EH. Colon cancer and apoptosis.Am J Surg 2006;191:517-26.
19. Fogh J, Fogh JM, Orfeo T. One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice. J Natl Cancer Inst 1977;59:221-6. (Pubitemid 8144854)
20. Zweibaum A, Laburthe M, Grasset E, Louvard D. Field M, Frizzell RA. editors.The Gastrointestinal System: Intestinal Absorption and Secretion. Handbook of Physiology. Bethesda, MD: American Physiology Society; 1991. p. 223-55.
21. Lesuffleur T, Kornowski A, Augeron C, Dussaulx E, Barbat A, Laboisse C, et al. Increased growth adaptability to 5-fluorouracil and methotrexate of HT-29 sub-populations selected for their commitment to differentiation. Int J Cancer 1991;49:731-7.
22. Violette S, Poulain L, Dussaulx E, Pepin D, Faussat AM, Chambaz J, et al. Resistance of colon cancer cells to long-term 5-fluorouracil exposure is correlated to the relative level of Bcl-2 and Bcl-X(L) in addition to Bax and p53 status. Int J Cancer 2002;98:498-504. (Pubitemid 34208549)
23. Maoret JJ, Anini Y, Rouyer-Fessard C, Gully D, Laburthe M. Neurotensin and a non-peptide neurotensin receptor antagonist control human colon cancer cell growth in cell culture and in cells xenografted into nude mice. Int J Cancer 1999;80:448-54. (Pubitemid 29019635)
24. Robin MA, Demeilliers C, Sutton A, Paradis V, Maisonneuve C, Dubois S, et al. Alcohol increases tumor necrosis factor alpha and decreases nuclear factor-kappab to activate hepatic apoptosis in genetically obese mice. Hepatology 2005;42:1280-90. (Pubitemid 43260030)
25. Pierce KL, Luttrell LM, Lefkowitz RJ. New mechanisms in heptahelical receptor signaling to mitogen activated protein kinase cascades. Oncogene 2001;20:1532-9. (Pubitemid 32336840)
26. Kirchgessner AL, Liu M. Orexin synthesis and response in the gut. Neuron 1999;24:941-51. (Pubitemid 30017673)
27. Segal NH, Saltz LB. Evolving treatment of advanced colon cancer. Annu Rev Med 2009;60:207-19.
28. Hanash SM. A role for chromosome 1 in colorectal cancer. Gastroenterology 1996;111:250-2. (Pubitemid 26226908)
29. Scartozzi M, Bearzi I, Berardi R, Mandolesi A, Fabris G, Cascinu S. Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: implications for treatment with EGFR-targeted monoclonal antibodies. J Clin Oncol 2004;22:4772-8.
30. Bralet MP, Paule B, Adam R, Guettier C. Loss of epidermal growth factor receptor expression in lymph node and liver metastases of colon carcinoma. J Clin Oncol 2005;23:5844-5.
31. Reubi JC, Maecke HR. Peptide-based probes for cancer imaging. J Nucl Med 2008;49:1735-8.
32. Reubi JC, Laderach U, Waser B, Gebbers JO, Robberecht P, Laissue JA. Vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptor subtypes in human tumors and their tissues of origin. Cancer Res 2000;60:3105-12. (Pubitemid 30395841)
33. Laburthe M, Rousset M, Boissard C, Chevalier G, Zweibaum A, Rosselin G. Vasoactive intestinal peptide: a potent stimulator of adenosine 30:50-cyclic monophosphate accumulation in gut carcinoma cell lines in culture. Proc Natl Acad Sci U S A 1978;75:2772-5. (Pubitemid 8374990)
34. Broyart JP, Dupont C, Laburthe M, Rosselin G. Characterization of vasoactive intestinal peptide receptors in human colonic epithelial cells. J Clin Endocrinol Metab 1981;52:715-21. (Pubitemid 13235891)
35. Salomon R, Couvineau A, Rouyer-Fessard C, Voisin T, Lavallee D, Blais A, et al. Characterization of a common VIP-PACAP receptor in human small intestinal epithelium. Am J Physiol 1993;264:E294-300.
36. Rodriguez-Henche N, Rodriguez-Pena MS, Guijarro LG, Prieto JC. Characterization of vasoactive intestinal peptide receptors in human liver. Biochim Biophys Acta 1994;1221:193-8.
37. Boivin B, Vaniotis G, Allen BG, Hebert TE. G protein-coupled receptors in and on the cell nucleus: a new signaling paradigm?J Recept Signal Transduct Res 2008;28:15-28.
38. Gobeil F, Fortier A, Zhu T, Bossolasco M, Leduc M, Grandbois M, et al. G-protein-coupled receptors signalling at the cell nucleus: an emerging paradigm. Can J Physiol Pharmacol 2006;84:287-97. (Pubitemid 44481092)
39. Achour L, Labbe-Jullie C, Scott MG, Marullo S. An escort for GPCRs: implications for regulation of receptor density at the cell surface. Trends Pharmacol Sci 2008;29:528-35.
40. Omary MB, Kagnoff MF. Identification of nuclear receptors for VIP on a human colonic adenocarcinoma cell line. Science 1987;238:1578-81. (Pubitemid 18032476)
41. Booden MA, Eckert LB, Der CJ, Trejo J. Persistent signaling by dysregulated thrombin receptor trafficking promotes breast carcinoma cell invasion. Mol Cell Biol 2004;24:1990-9. (Pubitemid 38248939)
42. Watson AJ. Apoptosis and colorectal cancer. Gut 2004;53:1701-9. (Pubitemid 39434118)
43. O'Connell J, Bennett MW, Nally K, Houston A, O'Sullivan GC, Shanahan F. Altered mechanisms of apoptosis in colon cancer: Fas resistance and counterattack in the tumor-immune conflict. Ann N Y Acad Sci 2000;910:178-92.
44. Boss C, Brisbare-Roch C, Jenck F. Biomedical application of orexin/ hypocretin receptor ligands in neuroscience. J Med Chem 2009;52: 891-903.